New Alternative to Spice Gold - Pep Spice
24\08\2008
p.e.p spice is a new and pleasing alternative to the very popular herbal incense mixes. p.e.p spice comes in 4 great essences that give a powerful fragrence when burned.
p.e.p spice is an exotic incense blend of the highest quality herbs and herbal extracts.
p.e.p spice has been developed and voted to give a stronger fragrance than other popular herbal incense mixes when burned so use sparingly in your incense burner.
EMCDDA to Decide on Future of Pep Pills
02\04\2007
Benzylpiperazine (BZP) , the active ingredient in Pep Pills, is to be the subject of a European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) risk assessment, the results of which will determine what, if any, control is placed on BZP throughout the European Union. The risk assessment comes about as the result of a joint Europol - EMCDDA report which concluded that BZP needs to be looked at in more detail. The results will be published in June 2007.
A Spiritual High spokesman said:
"We would like to extend a cautious welcome to the confirmation of the European risk assessment. There are many positives to take from the EMCDDA's pre-risk assessment report which we hope will feature when the full document is published. The main points are: that most adverse health effects occur when BZP is used with other substances; that because BZP is usually sold legally through shops and websites there is little or no organised crime associated with it; and that BZP appears to have no medical use, with no EU member state reporting that a licence to use BZP medically has ever been requested. This latter point is great news for the UK, where the Medicines and Healthcare products Regulatory Agency (MHRA) is currently suggesting that BZP is a medicine."
"Importantly the EMCDDA also appears to believe that the best evidence about BZP comes from New Zealand 'where the longer history and the legal status of the phenomenon allowed it to be better studied'. This is excellent news. In New Zealand BZP has shown that regulation of recreational substances can be a better alternative to prohibition. Two sets of independent research into the social consequences of BZP now show that BZP is proven to be safer than illegal drugs, proven to reduce use of illegal drugs and proven to help existing drug users stop using illegal drugs. With 20 million plus pills consumed over 7 years with no deaths, BZP also has an exemplary safety record. We hope the EMCDDA will take note."
"In its conclusion the report also mentions that the consequences of applying control to BZP should be considered before any decision is reached. This is potentially of vital importance. BZP is not like other drugs, in the UK it has always been seen as a 'legal high' that provides an effective alternative to illegal drugs for people who don't want to break the law. By banning it that alternative will be removed. We urge any Pep Pills user who would like to see them legally available to contact the EMCDDA and tell them exactly how a ban on BZP would affect them. If enough people speak up, the EMCDDA will have to listen."
Links
Special Announcement - Sales of Pep Pills Suspended
13\09\2006
We would like to announce that we have suspended all UK sales of Pep Pills due to a Medicines and Healthcare products Regulatory Agency (MHRA) investigation into their legality under the Medicines Act (1968). We are cooperating with the MHRA about this matter and strongly advise consumers and retailers NOT to buy or sell Pep Pills until the issue has been resolved.
The MHRA is investigating whether or not Pep Pills are licensable under the Medicines Act (1968) on the basis of their ingredients, labelling or use. In particular the MHRA has expressed concern that Pep Pills may contain the licensed medicine Piperazine which is a veterinary worming treatment.
We can assure our customers that Pep Pills do NOT contain Piperazine and that an independent chemical analysis has confirmed this. It appears that the MHRA has failed to distiguish between Piperazine and a number of other substances in the same family, which are not currently licensed medicines.
Whilst we recognise that the MHRA has a duty to protect consumers and welcome any step that helps to protect them from risks, we would like to point out that Pep Pills do not have any recognised medical use, and are therefore unsuitable for regulation by the MHRA. We propose that products such as Pep Pills need regulation that recognises them for what they are, not foods, not medicines, but recreational substances. We suggest that the New Zealand model, where Pep Pills are scheduled as 'Class D Restricted Substances' and legally available to over 18s, is a good place to start.
ACMD Refers Benzylpiperazine (BZP) Issue to Europe
12\12\2006
The Secretary of the Advisory Council on the Misues of Drugs (ACMD) has informed Spiritual High Ltd that any UK recommendations on the future of Benzylpiperazine (BZP), the active ingredients in our Pep Pills range, must wait until a risk assessment and review by the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). The EMCDDA is the central source of comprehensive information on drugs and drug addiction to all member states of the European Union.
The ACMD Secretary stated:
"At its last Technical Committee meeting in November the ACMD concluded that the issue of BZP was an area that needed further dedicated work, but that the Council should await the conclusion of the EMCDDA risk assessment (due in the New Year) before embarking on any specific work-streams.
The Technical Committee was, however, prepared to establish a BZP working group at short notice if there was a specific need to do so.
The ACMD have just received confirmation that the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) has taken the first steps in a process that may lead to risk assessment and possible control of BZP throughout the EU."
A Spiritual High Spokesman made the following statement:
"We would like to extend a cautious welcome to the news that the EMCDDA will be assessing Benzylpiperazine. As a non-executive body limited to making recommendations based on evidence, the EMCDDA is exactly the kind of organisation that we want to be looking at drug policy, and has a history of making made informed, objective judgements free of political bias.
We are equally we are glad that the ACMD has decided that BZP is an issue that falls under their remit. BZP is not a food or a medicine and any decisions about it should be made on that basis. The ACMD has made the right decision.
However, this doesn't mean anything more than a new stage in our campaign, and that one way or another a decision on BZP in the UK will be made in the next year. What we still have to do is make sure that the right decision is made. Even if the EMCDDA conclude that BZP poses no significant risk to consumers there is no guarantee that the UK government will act according to that finding. There is still the possibility that prohibition remains the standard response to the emergence of any new substance, whatever the evidence surrounding it might be. We will continue to work to make sure that the evidence is considered.
We will now be extending our lobbying activity to the EMCDDA and other European organisations, and continuing our dialogue with the ACMD. We urge anyone who distributes or uses BZP products to get behind our campaign and help us change drug policy for the better."
ACMD Refers Benzylpiperazine (BZP) Issue to Europe
12\12\2006
The Secretary of the Advisory Council on the Misues of Drugs (ACMD) has informed Spiritual High Ltd that any UK recommendations on the future of Benzylpiperazine (BZP), the active ingredients in our Pep Pills range, must wait until a risk assessment and review by the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). The EMCDDA is the central source of comprehensive information on drugs and drug addiction to all member states of the European Union.
The ACMD Secretary stated:
"At its last Technical Committee meeting in November the ACMD concluded that the issue of BZP was an area that needed further dedicated work, but that the Council should await the conclusion of the EMCDDA risk assessment (due in the New Year) before embarking on any specific work-streams.
The Technical Committee was, however, prepared to establish a BZP working group at short notice if there was a specific need to do so.
The ACMD have just received confirmation that the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) has taken the first steps in a process that may lead to risk assessment and possible control of BZP throughout the EU."
A Spiritual High Spokesman made the following statement:
"We would like to extend a cautious welcome to the news that the EMCDDA will be assessing Benzylpiperazine. As a non-executive body limited to making recommendations based on evidence, the EMCDDA is exactly the kind of organisation that we want to be looking at drug policy, and has a history of making made informed, objective judgements free of political bias.
We are equally we are glad that the ACMD has decided that BZP is an issue that falls under their remit. BZP is not a food or a medicine and any decisions about it should be made on that basis. The ACMD has made the right decision.
However, this doesn't mean anything more than a new stage in our campaign, and that one way or another a decision on BZP in the UK will be made in the next year. What we still have to do is make sure that the right decision is made. Even if the EMCDDA conclude that BZP poses no significant risk to consumers there is no guarantee that the UK government will act according to that finding. There is still the possibility that prohibition remains the standard response to the emergence of any new substance, whatever the evidence surrounding it might be. We will continue to work to make sure that the evidence is considered.
We will now be extending our lobbying activity to the EMCDDA and other European organisations, and continuing our dialogue with the ACMD. We urge anyone who distributes or uses BZP products to get behind our campaign and help us change drug policy for the better."
Heroin on the NHS a Great Idea
24\11\2006
One of the UK's largest manufacturers of so-called 'legal highs' today welcomed recent proposals from Deputy Chief Constable Howard Roberts to provide heroin free to drug addicts on the NHS. Spiritual High Ltd, who are campaigning for the introduction of a legal 'Class D' drug classification category to accommodate low-risk recreational substances, said that the proposals highlighted the need for a rational and informed debate on the future of UK drug policy.
"We think that providing heroin on the NHS is a great idea," their spokesman said. "Whatever people's misgivings about the idea of handing out drugs to addicts, no-one can argue with the fact that heroin addiction is one of the UK's largest causes of crime. If prescribing heroin prevents addicts from stealing then surely it is the right thing to do. People need to look past the 'yuck factor' they feel when thinking about drug use and realise that the problem lies not with the substances themselves, but with the harm that they cause to society. What is more important: whether or not someone uses drugs, or whether or not they commit crime as a result?"
He went on:
"To hear common-sense ideas like this coming from top law enforcement can only be a good thing. For too long drug policy in this country has been based on sending a political message about being 'tough on drugs', without any real debate about what that policy is actually meant to achieve. Many people consider drug use to be morally wrong, but is that really a sufficient basis for penalising the many people who do not? These are questions we need to ask ourselves as a society."
"Our campaign for a legal 'Class D' drug category is based on exactly these ideas. Just as with the prescription of heroin on the NHS, the provision of legal alternatives to illicit drugs offers drug users the chance to opt out of criminal activity and all the risks such activity brings with it. By walking into a shop and buying, say, a packet of our Pep Pills legal highs, consumers are actively turning their back on the illicit drugs market and choosing an alternative that is labelled, quality tested and has full ingredients, safety and dosage instructions. Although many people may feel unease at the idea of someone buying any product designed to get them high, no-one can deny that such a system carries vastly fewer risks than one in which the only option is to buy illicit drugs. We hope that those who back the idea of providing heroin on the NHS will also back our campaign for a Class D drug category for low-risk substances."
Advice Submitted to ACMD Technical Committee BZP Meeting
25\10\2006
At the invitation of the Home Office, we have formally submitted our advice on Benzylpiperazine (BZP) for consideration at the Advisory Council on the Misuse of Drugs (ACMD) Technical Committee's initial review of Benzylpiperazine.
The ACMD Technical Committee will be examining the issues surrounding BZP in order to determine whether the ACMD should undertake further examination of the substance. Our submitted document "Benzylpiperazine Industry Advice to the ACMD on Benzylpiperazine" presents statistical evidence from New Zealand demonstrating that Benzylpiperazine is a low risk substance, describes the structure of the UK Benzylpiperazine industry and discusses several policy options for dealing with Benzylpiperazine.
Our spokesman made the following statement:
"We are absolutely delighted that the Home Office has asked us to submit to the Benzylpiperazine meeting. It shows that policy makers are now starting to look at the evidence surrounding recreational drug use instead of making knee-jerk responses to scare stories in the media.'"
"All the evidence shows that Benzylpiperazine use is an extremely low risk activity. No-one has ever died or been seriously harmed as a result of using it, and it has helped large numbers of drug users to stop taking illicit drugs. By allowing the regulated sale and use of BZP in a recreational context the Government would substantially reduce trade in illicit drugs as well as helping to protect drug users from unneccessary risks."
"This meeting is a golden opportunity for the UK to develop a modern, harm reduction centred drug policy that actually works."
To view our submitted document, click the link below. To download a copy, right click and "Save Target As..."
Benzylpiperazine Industry Advice to the ACMD on Benzylpiperazine